Cargando…
Creation of nano eye-drops and effective drug delivery to the interior of the eye
Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-si...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349510/ https://www.ncbi.nlm.nih.gov/pubmed/28290486 http://dx.doi.org/10.1038/srep44229 |
_version_ | 1782514479432466432 |
---|---|
author | Ikuta, Yoshikazu Aoyagi, Shigenobu Tanaka, Yuji Sato, Kota Inada, Satoshi Koseki, Yoshitaka Onodera, Tsunenobu Oikawa, Hidetoshi Kasai, Hitoshi |
author_facet | Ikuta, Yoshikazu Aoyagi, Shigenobu Tanaka, Yuji Sato, Kota Inada, Satoshi Koseki, Yoshitaka Onodera, Tsunenobu Oikawa, Hidetoshi Kasai, Hitoshi |
author_sort | Ikuta, Yoshikazu |
collection | PubMed |
description | Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment. |
format | Online Article Text |
id | pubmed-5349510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53495102017-03-17 Creation of nano eye-drops and effective drug delivery to the interior of the eye Ikuta, Yoshikazu Aoyagi, Shigenobu Tanaka, Yuji Sato, Kota Inada, Satoshi Koseki, Yoshitaka Onodera, Tsunenobu Oikawa, Hidetoshi Kasai, Hitoshi Sci Rep Article Nano eye-drops are a new type of ophthalmic treatment with increased potency and reduced side effects. Compounds in conventional eye-drops barely penetrate into the eye because the cornea, located at the surface of eye, has a strong barrier function for preventing invasion of hydrophilic or large-sized materials from the outside. In this work, we describe the utility of nano eye-drops utilising brinzolamide, a commercially available glaucoma treatment drug, as a target compound. Fabrication of the nanoparticles of brinzolamide prodrug increases the eye penetration rate and results in high drug efficacy, compared with that of commercially available brinzolamide eye-drops formulated as micro-sized structures. In addition, the resulting nano eye-drops were not toxic to the corneal epithelium after repeated administration for 1 week. The nano eye-drops may have applications as a next-generation ophthalmic treatment. Nature Publishing Group 2017-03-14 /pmc/articles/PMC5349510/ /pubmed/28290486 http://dx.doi.org/10.1038/srep44229 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Ikuta, Yoshikazu Aoyagi, Shigenobu Tanaka, Yuji Sato, Kota Inada, Satoshi Koseki, Yoshitaka Onodera, Tsunenobu Oikawa, Hidetoshi Kasai, Hitoshi Creation of nano eye-drops and effective drug delivery to the interior of the eye |
title | Creation of nano eye-drops and effective drug delivery to the interior of the eye |
title_full | Creation of nano eye-drops and effective drug delivery to the interior of the eye |
title_fullStr | Creation of nano eye-drops and effective drug delivery to the interior of the eye |
title_full_unstemmed | Creation of nano eye-drops and effective drug delivery to the interior of the eye |
title_short | Creation of nano eye-drops and effective drug delivery to the interior of the eye |
title_sort | creation of nano eye-drops and effective drug delivery to the interior of the eye |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349510/ https://www.ncbi.nlm.nih.gov/pubmed/28290486 http://dx.doi.org/10.1038/srep44229 |
work_keys_str_mv | AT ikutayoshikazu creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye AT aoyagishigenobu creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye AT tanakayuji creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye AT satokota creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye AT inadasatoshi creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye AT kosekiyoshitaka creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye AT onoderatsunenobu creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye AT oikawahidetoshi creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye AT kasaihitoshi creationofnanoeyedropsandeffectivedrugdeliverytotheinterioroftheeye |